ebbu’s phytogenics are reshaping
how cannabis is cultivated
and rare cannabinoid production
ebbu is reinventing the holy grail of cannabis—the strain.
For thousands of years, people have relied on the natural world to produce unique varieties of cannabis, each with varying chemical compositions. Today, ebbu’s genetics division is transcending the strain by moving beyond what is only available in the natural environment.
After years of groundbreaking work, ebbu scientists can genetically target candidate genes to significantly increase trichome expression and rare cannabinoid production in marijuana and hemp plants. This will reinvent the global supply chain for cannabinoids, both expanding the number of commercially available cannabinoids and drastically reducing the costs.
Genetic editing revolution
ebbu is revolutionizing cultivation practices through genetic editing. Using genome editing tool CRISPR / Cas9 in combination with its own proprietary genetic tool sets, ebbu scientists can go from genetic computer models to live genetic experiments in two weeks at ebbu’s state-of-the-art research laboratory in the Colorado Rockies. The ebbu team is developing plants with:
● An overexpression of plant trichomes, not just focused on the flower but also on fan leaves
● Commercially-viable volumes of rare cannabinoids, many of which can be extracted from less-regulated hemp plants
Cannabis potency to-date has been strain-dependent, which puts pressure on cultivation costs. ebbu is driving down costs by creating plants that overexpress trichomes, which house all of the cannabinoids. By increasing trichome density, cultivators can increase their potency by 200-1,000%, decrease cultivation costs by up to 80% and scale up their commercial grows.
Cannabis plants produce dozens of naturally-occurring cannabinoids that interact with the human endocannabinoid system in ways that ebbu scientists are beginning to tap into. Most cannabis plants—marijuana and hemp—are bred primarily to express only two cannabinoids: THC and CBD. Lesser-known cannabinoids—like CBC, CBG, CBDV, CBGV, THCV and dozens more—are the building blocks for an infinite number of pharmacological and commercial uses but have continued to be genetically marginalized.
The ebbu team can provide cultivators with a range of cannabis DNA that has been genetically edited to overproduce rare cannabinoids, allowing for bulk production of these lesser-known cannabinoids for pharmaceutical and recreational applications. Even better: Many of these non-THC cannabinoids can be cultivated in hemp plants, saving businesses money and headaches in a less-regulated space.